We are live on ! Find out more
EP

Elkfork Partners Portfolio holdings

AUM $4.11B
1-Year Est. Return 5.26%
This Fund
S&P 500
This Quarter Est. Return
-13.25%
1 Year Est. Return
+5.26%
3 Year Est. Return
+52.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.55B
AUM Growth
-$661M
Cap. Flow
-$52.1M
Cap. Flow %
-1.47%
Top 10 Hldgs %
24.55%
Holding
1,098
New
85
Increased
374
Reduced
258
Closed
83

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$32.1M
2
COP icon
ConocoPhillips
COP
+$17.9M
3
LIN icon
Linde
LIN
+$17.1M
4
XOM icon
ExxonMobil
XOM
+$15.1M
5
FTNT icon
Fortinet
FTNT
+$11.1M

Top Sells

Rank Stock Value
1
ESRX
Express Scripts Holding Company
ESRX
+$51.2M
2
PX
Praxair Inc
PX
+$24.6M
3
SLB icon
SLB Ltd
SLB
+$16.4M
4
HUM icon
Humana
HUM
+$10.3M
5
CELG
Celgene Corp
CELG
+$9.53M

Sector Composition

Rank Sector Weight
1 Technology 18.48%
2 Financials 15.73%
3 Healthcare 13.18%
4 Consumer Discretionary 13.17%
5 Industrials 10.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCTY icon
1001
Paylocity
PCTY
$7.38B
$13K ﹤0.01%
+220
New +$14.1K
SAP icon
1002
SAP
SAP
$212B
$13K ﹤0.01%
132
-10,142
-99% -$1.08M
RP
1003
DELISTED
RealPage, Inc.
RP
$13K ﹤0.01%
+264
New +$13.8K
PAYC icon
1004
Paycom
PAYC
$7.64B
$11K ﹤0.01%
+88
New +$11.3K
RETA
1005
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$11K ﹤0.01%
+198
New +$12.1K
DNTH icon
1006
Dianthus Therapeutics
DNTH
$5.84B
$10K ﹤0.01%
105
-85
-45% -$11.6K
VCIT icon
1007
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
$66.2B
$9K ﹤0.01%
112
– –
TARA icon
1008
Protara Therapeutics
TARA
$220M
$7K ﹤0.01%
+72
New +$5.08K
ARRY
1009
DELISTED
Array Biopharma Inc
ARRY
$6K ﹤0.01%
+408
New +$6.19K
MDGL icon
1010
Madrigal Pharmaceuticals
MDGL
$10.8B
$5K ﹤0.01%
+44
New +$6.81K
SCG
1011
DELISTED
Scana
SCG
$4K ﹤0.01%
88
-616
-88% -$26.5K
PTGX icon
1012
Protagonist Therapeutics
PTGX
$8.79B
$3K ﹤0.01%
+442
New +$3.51K
ARVN icon
1013
Arvinas
ARVN
$518M
$2K ﹤0.01%
+170
New +$2.7K
SRRK icon
1014
Scholar Rock
SRRK
$5.67B
$2K ﹤0.01%
+110
New +$2.49K
TPST icon
1015
Tempest Therapeutics
TPST
$13.7M
$2K ﹤0.01%
1
-1
-50% -$2.06K
AEG icon
1016
Aegon
AEG
$14B
– –
-40,603
Closed -$224K
ASRT
1017
DELISTED
Assertio
ASRT
– –
-275
Closed -$97K
BBVA icon
1018
Banco Bilbao Vizcaya Argentaria
BBVA
$154B
– –
-48,598
Closed -$306K
BILI icon
1019
Bilibili
BILI
$7.99B
– –
-16,116
Closed -$217K
BLUE
1020
DELISTED
bluebird bio
BLUE
– –
-575
Closed -$1.09M
BP icon
1021
BP
BP
$116B
– –
-10,000
Closed -$440K
BTE icon
1022
Baytex Energy
BTE
$3.25B
– –
-1,736
Closed -$5K
CE icon
1023
Celanese
CE
$4.9B
– –
-550
Closed -$63K
CRH icon
1024
CRH
CRH
$63.2B
– –
-4,704
Closed -$154K
CSTE icon
1025
Caesarstone
CSTE
$72.3M
– –
-1,484
Closed -$28K
39 40
41
42 43

Similar funds

GHCM
Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return
FCM
Flinton Capital Management Philadelphia, Pennsylvania $3.22B AUM 4.75% 1-Year Est. Return
NA
Neuburgh Advisers Los Angeles, California $3.22B AUM 3.74% 1-Year Est. Return
FIM
Foresters Investment Management New York $5.05B AUM 5.06% 1-Year Est. Return
MCIM
Meadow Creek Investment Management Atlanta, Georgia $5.09B AUM 5.82% 1-Year Est. Return
TAM
Tyers Asset Management Austin, Texas $3.02B AUM 5.29% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
RCM
Riverhead Capital Management Wilmington, Delaware $2.71B AUM 2.34% 1-Year Est. Return

Elkfork Partners's Q4 2018 Portfolio in Review

As of Q4 2018, Elkfork Partners held 1,098 positions worth $3.55B, down 16% from $4.21B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Elkfork Partners's Q4 2018 filing shows 85 new, 374 increased, 258 reduced and 83 closed positions. Its largest new stake was Linde: 108,108 shares worth $16.9M. The largest sale was Express Scripts Holding Company, an estimated $51.2M.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.

  • Elkfork Partners's largest Q4 2018 buy was Linde: 108,108 shares worth $16.9M.
  • Elkfork Partners added most to Cigna in Q4 2018, an estimated $32.1M increase.
  • Elkfork Partners's biggest Q4 2018 reduction was SLB Ltd, cutting an estimated $16.4M.
  • Elkfork Partners fully exited Express Scripts Holding Company in Q4 2018, selling an estimated $51.2M.
  • Elkfork Partners's ten largest holdings make up 25% of its $3.55B portfolio in Q4 2018.
  • Elkfork Partners opened 85 new positions and closed 83 in Q4 2018.
  • Elkfork Partners's portfolio value fell 16% quarter-over-quarter to $3.55B.

Based on Elkfork Partners's 13F filing for Q4 2018, filed 13 Feb 2019.